Statins potentiate cytostatic/cytotoxic activity of sorafenib but not sunitinib against tumor cell lines in vitro

Cancer Letters

Volumn 288, Issue 1, 2010, Pages 57-67

  Bil, Jacek ^a   Zapala, Lukasz ^a   Nowis, Dominika ^a   Jakobisiak, Marek ^a   Golab, Jakub ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Cardiotoxic effect; Cytostatic cytotoxic effect; Sorafenib; Statins; Sunitinib

Indexed keywords

2 [[2 [[2 [(2 AMINO 3 MERCAPTOPROPYL)AMINO] 3 METHYLPENTYL]OXY] 1 OXO 3 PHENYLPROPYL]AMINO] 4 (METHYLSULFONYL)BUTANOIC ACID ISOPROPYL ESTER; ATORVASTATIN; CERIVASTATIN; COMPACTIN; FLUINDOSTATIN; GGTI 298; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PROTEIN TYROSINE KINASE INHIBITOR; SIMVASTATIN; SORAFENIB; SUNITINIB;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CARDIOTOXICITY; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE REGULATION; CONTROLLED STUDY; CYTOSTASIS; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG POTENTIATION; HEART FUNCTION; HEART MUSCLE CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN MODIFICATION; PROTEIN PRENYLATION; RAT; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; BENZENESULFONATES; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FLOW CYTOMETRY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; LOVASTATIN; MICE; MYOCYTES, CARDIAC; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN PRENYLATION; PYRIDINES; PYRROLES; RATS;

RATTUS;

EID: 73649086945     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.06.022     Document Type: Article

References (57)

1. Wang C.Y., Liu P.Y., and Liao J.K. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol. Med. 14 (2008) 37-44
2. M. Jakobisiak, J. Golab, Statins can modulate effectiveness of antitumor therapeutic modalities, Med. Res. Rev. (2009) [Epub ahead of print].
3. Jakobisiak M., Bruno S., Skierski J.S., and Darzynkiewicz Z. Cell cycle-specific effects of lovastatin. Proc. Natl. Acad. Sci. USA 88 (1991) 3628-3632
4. Maksimova E., Yie T.A., and Rom W.N. In vitro mechanisms of lovastatin on lung cancer cell lines as a potential chemopreventive agent. Lung 186 (2008) 45-54
5. von Tresckow B., von Strandmann E.P., Sasse S., Tawadros S., Engert A., and Hansen H.P. Simvastatin-dependent apoptosis in Hodgkin's lymphoma cells and growth impairment of human Hodgkin's tumors in vivo. Haematologica 92 (2007) 682-685
6. Holstein S.A., and Hohl R.J. Synergistic interaction of lovastatin and paclitaxel in human cancer cells. Mol. Cancer Ther. 1 (2001) 141-149
7. Kozar K., Kaminski R., Legat M., Kopec M., Nowis D., Skierski J.S., Koronkiewicz M., Jakobisiak M., and Golab J. Cerivastatin demonstrates enhanced antitumor activity against human breast cancer cell lines when used in combination with doxorubicin or cisplatin. Int. J. Oncol. 24 (2004) 1149-1157
8. Bocci G., Fioravanti A., Orlandi P., Bernardini N., Collecchi P., Del Tacca M., and Danesi R. Fluvastatin synergistically enhances the antiproliferative effect of gemcitabine in human pancreatic cancer MIAPaCa-2 cells. Br. J. Cancer 93 (2005) 319-330
9. Budman D.R., Tai J., and Calabro A. Fluvastatin enhancement of trastuzumab and classical cytotoxic agents in defined breast cancer cell lines in vitro. Breast Cancer Res. Treat. 104 (2007) 93-101
10. Issat T., Nowis D., Legat M., Makowski M., Klejman M.P., Urbanski J., Skierski J., Koronkiewicz M., Stoklosa T., Brzezinska A., Bil J., Gietka J., Jakobisiak M., and Golab J. Potentiated antitumor effects of the combination treatment with statins and pamidronate in vitro and in vivo. Int. J. Oncol. 30 (2007) 1413-1425
11. Calabro A., Tai J., Allen S.L., and Budman D.R. In-vitro synergism of m-TOR inhibitors, statins, and classical chemotherapy: potential implications in acute leukemia. Anticancer Drugs 19 (2008) 705-712
12. Fuchs D., Berges C., Opelz G., Daniel V., and Naujokat C. HMG-CoA reductase inhibitor simvastatin overcomes bortezomib-induced apoptosis resistance by disrupting a geranylgeranyl pyrophosphate-dependent survival pathway. Biochem. Biophys. Res. Commun. 374 (2008) 309-314
13. Feleszko W., Mlynarczuk I., Balkowiec-Iskra E.Z., Czajka A., Switaj T., Stoklosa T., Giermasz A., and Jakobisiak M. Lovastatin potentiates antitumor activity and attenuates cardiotoxicity of doxorubicin in three tumor models in mice. Clin. Cancer Res. 6 (2000) 2044-2052
14. Winiarska M., Bil J., Wilczek E., Wilczynski G.M., Lekka M., Engelberts P.J., Mackus W.J., Gorska E., Bojarski L., Stoklosa T., Nowis D., Kurzaj Z., Makowski M., Glodkowska E., Issat T., Mrowka P., Lasek W., Dabrowska-Iwanicka A., Basak G.W., Wasik M., Warzocha K., Sinski M., Gaciong Z., Jakobisiak M., Parren P.W., and Golab J. Statins impair antitumor effects of rituximab by inducing conformational changes of CD20. PLoS Med. 5 (2008) e64
15. Alsheikh-Ali A.A., Trikalinos T.A., Kent D.M., and Karas R.H. Statins, low-density lipoprotein cholesterol, and risk of cancer. J. Am. Coll. Cardiol. 52 (2008) 1141-1147
16. Coogan P.F., Rosenberg L., Palmer J.R., Strom B.L., Zauber A.G., and Shapiro S. Statin use and the risk of breast and prostate cancer. Epidemiology 13 (2002) 262-267
17. El-Seraq H.B., Johnson M.L., Hachem C., and Morgan R.O. Statins are associated with a reduced risk of hepatocellular carcinomain a large cohort of patients with diabetes. Gastroenterology (2009)
18. Platz E.A. Does statin use affect the risk of developing prostate cancer?. Nat. Clin. Pract. Urol. 6 (2009) 70-71
19. Wilkins T., and Reynolds P.L. Colorectal cancer: a summary of the evidence for screening and prevention. Am. Fam. Physician 78 (2008) 1385-1392
20. Wilhelm S.M., Carter C., Tang L., Wilkie D., McNabola A., Rong H., Chen C., Zhang X., Vincent P., McHugh M., Cao Y., Shujath J., Gawlak S., Eveleigh D., Rowley B., Liu L., Adnane L., Lynch M., Auclair D., Taylor I., Gedrich R., Voznesensky A., Riedl B., Post L.E., Bollag G., and Trail P.A. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64 (2004) 7099-7109
21. Carlomagno F., Anaganti S., Guida T., Salvatore G., Troncone G., Wilhelm S.M., and Santoro M. BAY 43-9006 inhibition of oncogenic RET mutants. J. Natl. Cancer Inst. 98 (2006) 326-334
22. Rahmani M., Davis E.M., Bauer C., Dent P., and Grant S. Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. J. Biol. Chem. 280 (2005) 35217-35227
23. Kloos R.T., Ringel M.D., Knopp M.V., Hall N.C., King M., Stevens R., Liang J., Wakely Jr. P.E., Vasko V.V., Saji M., Rittenberry J., Wei L., Arbogast D., Collamore M., Wright J.J., Grever M., and Shah M.H. Phase II trial of sorafenib in metastatic thyroid cancer. J. Clin. Oncol. (2009)
24. Aragon-Ching J.B., Jain L., Gulley J.L., Arlen P.M., Wright J.J., Steinberg S.M., Draper D., Venitz J., Jones E., Chen C.C., Figg W.D., and Dahut W.L. Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. BJU Int. (2009)
25. Moreno-Aspitia A., Morton R.F., Hillman D.W., Lingle W.L., Rowland Jr. K.M., Wiesenfeld M., Flynn P.J., Fitch T.R., and Perez E.A. Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336. J. Clin. Oncol. 27 (2009) 11-15
26. Elser C., Siu L.L., Winquist E., Agulnik M., Pond G.R., Chin S.F., Francis P., Cheiken R., Elting J., McNabola A., Wilkie D., Petrenciuc O., and Chen E.X. Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J. Clin. Oncol. 25 (2007) 3766-3773
27. Flaherty K.T., Schiller J., Schuchter L.M., Liu G., Tuveson D.A., Redlinger M., Lathia C., Xia C., Petrenciuc O., Hingorani S.R., Jacobetz M.A., Van Belle P.A., Elder D., Brose M.S., Weber B.L., Albertini M.R., and O'Dwyer P.J. A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel. Clin. Cancer Res. 14 (2008) 4836-4842
28. Escudier B., Szczylik C., Hutson T.E., Demkow T., Staehler M., Rolland F., Negrier S., Laferriere N., Scheuring U.J., Cella D., Shah S., and Bukowski R.M. Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27 (2009) 1280-1289
29. Azad N.S., Posadas E.M., Kwitkowski V.E., Steinberg S.M., Jain L., Annunziata C.M., Minasian L., Sarosy G., Kotz H.L., Premkumar A., Cao L., McNally D., Chow C., Chen H.X., Wright J.J., Figg W.D., and Kohn E.C. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J. Clin. Oncol. 26 (2008) 3709-3714
30. Duran I., Hotte S.J., Hirte H., Chen E.X., MacLean M., Turner S., Duan L., Pond G.R., Lathia C., Walsh S., Wright J.J., Dancey J., and Siu L.L. Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors. Clin. Cancer Res. 13 (2007) 4849-4857
31. Faivre S., Demetri G., Sargent W., and Raymond E. Molecular basis for sunitinib efficacy and future clinical development. Nat. Rev. Drug Discov. 6 (2007) 734-745
32. Mendel D.B., Laird A.D., Xin X., Louie S.G., Christensen J.G., Li G., Schreck R.E., Abrams T.J., Ngai T.J., Lee L.B., Murray L.J., Carver J., Chan E., Moss K.G., Haznedar J.O., Sukbuntherng J., Blake R.A., Sun L., Tang C., Miller T., Shirazian S., McMahon G., Cherrington J.M., and SU11248 I.v.a.a.o. a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 9 (2003) 327-337
33. Osusky K.L., Hallahan D.E., Fu A., Ye F., Shyr Y., and Geng L. The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo but has little effect on existing tumor vessels. Angiogenesis 7 (2004) 225-233
34. Sonpavde G., Hutson T.E., Berry W.R., Boehm K.A., and Asmar L. Phase II trial of sunitinib for the therapy of progressive metastatic castration-refractory prostate cancer after previous docetaxel chemotherapy. Clin. Genitourin. Cancer 6 (2008) 134-137
35. Socinski M.A. The current status and evolving role of sunitinib in non-small cell lung cancer. J. Thorac. Oncol. 3 (2008) S119-123
36. Burstein H.J., Elias A.D., Rugo H.S., Cobleigh M.A., Wolff A.C., Eisenberg P.D., Lehman M., Adams B.J., Bello C.L., DePrimo S.E., Baum C.M., and Miller K.D. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J. Clin. Oncol. 26 (2008) 1810-1816
37. Feldman D.R., Baum M.S., Ginsberg M.S., Hassoun H., Flombaum C.D., Velasco S., Fischer P., Ronnen E., Ishill N., Patil S., and Motzer R.J. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27 (2009) 1432-1439
38. Motzer R.J., Hudes G., Wilding G., Schwartz L.H., Hariharan S., Kempin S., Fayyad R., and Figlin R.A. Phase I trial of sunitinib malate plus interferon-alpha for patients with metastatic renal cell carcinoma. Clin. Genitourin. Cancer 7 (2009) 28-33
39. Patel P.H., Senico P.L., Curiel R.E., and Motzer R.J. Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma. Clin. Genitourin. Cancer 7 (2009) 24-27
40. Nishioka C., Ikezoe T., Yang J., Takeshita A., Taniguchi A., Komatsu N., Togitani K., Koeffler H.P., and Yokoyama A. Blockade of MEK/ERK signaling enhances sunitinib-induced growth inhibition and apoptosis of leukemia cells possessing activating mutations of the FLT3 gene. Leuk. Res. 32 (2008) 865-872
41. Wu J., Wong W.W., Khosravi F., Minden M.D., and Penn L.Z. Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis. Cancer Res. 64 (2004) 6461-6468
42. Chou T.C., and Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22 (1984) 27-55
43. Mann D., Reynolds K., Smith D., and Muntner P. Trends in statin use and low-density lipoprotein cholesterol levels among US adults: impact of the 2001 national cholesterol education program guidelines. Ann. Pharmacother. 42 (2008) 1208-1215
44. Thibault A., Samid D., Tompkins A.C., Figg W.D., Cooper M.R., Hohl R.J., Trepel J., Liang B., Patronas N., Venzon D.J., Reed E., and Myers C.E. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin. Cancer Res. 2 (1996) 483-491
45. Holstein S.A., Knapp H.R., Clamon G.H., Murry D.J., and Hohl R.J. Pharmacodynamic effects of high dose lovastatin in subjects with advanced malignancies. Cancer Chemother. Pharmacol. 57 (2006) 155-164
46. Clark J.W., Eder J.P., Ryan D., Lathia C., and Lenz H.J. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin. Cancer Res. 11 (2005) 5472-5480
47. O'Farrell A.M., Foran J.M., Fiedler W., Serve H., Paquette R.L., Cooper M.A., Yuen H.A., Louie S.G., Kim H., Nicholas S., Heinrich M.C., Berdel W.E., Bello C., Jacobs M., Scigalla P., Manning W.C., Kelsey S., and Cherrington J.M. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin. Cancer Res. 9 (2003) 5465-5476
48. Ulivi P., Arienti C., Amadori D., Fabbri F., Carloni S., Tesei A., Vannini I., Silvestrini R., and Zoli W. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines. J. Cell Physiol. (2009)
49. Park S.J., Kim Y.Y., Lim J.Y., Seo G.J., Kim J., Park S.I., and Park B.J. Opposite role of Ras in tumor necrosis factor-alpha-induced cell cycle regulation: competition for Raf kinase. Biochem. Biophys. Res. Commun. 287 (2001) 1140-1147
50. Force T., Krause D.S., and Van Etten R.A. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat. Rev. Cancer 7 (2007) 332-344
51. Schmidinger M., Zielinski C.C., Vogl U.M., Bojic A., Bojic M., Schukro C., Ruhsam M., Hejna M., and Schmidinger H. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 26 (2008) 5204-5212
52. Yamaguchi O., Watanabe T., Nishida K., Kashiwase K., Higuchi Y., Takeda T., Hikoso S., Hirotani S., Asahi M., Taniike M., Nakai A., Tsujimoto I., Matsumura Y., Miyazaki J., Chien K.R., Matsuzawa A., Sadamitsu C., Ichijo H., Baccarini M., Hori M., and Otsu K. Cardiac-specific disruption of the c-raf-1 gene induces cardiac dysfunction and apoptosis. J. Clin. Invest. 114 (2004) 937-943
53. Harris I.S., Zhang S., Treskov I., Kovacs A., Weinheimer C., and Muslin A.J. Raf-1 kinase is required for cardiac hypertrophy and cardiomyocyte survival in response to pressure overload. Circulation 110 (2004) 718-723
54. Will Y., Dykens J.A., Nadanaciva S., Hirakawa B., Jamieson J., Marroquin L.D., Hynes J., Patyna S., and Jessen B.A. Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells. Toxicol. Sci. 106 (2008) 153-161
55. Damrot J., Nubel T., Epe B., Roos W.P., Kaina B., and Fritz G. Lovastatin protects human endothelial cells from the genotoxic and cytotoxic effects of the anticancer drugs doxorubicin and etoposide. Br. J. Pharmacol. 149 (2006) 988-997
56. Nubel T., Damrot J., Roos W.P., Kaina B., and Fritz G. Lovastatin protects human endothelial cells from killing by ionizing radiation without impairing induction and repair of DNA double-strand breaks. Clin. Cancer Res. 12 (2006) 933-939
57. Johnson-Anuna L.N., Eckert G.P., Franke C., Igbavboa U., Muller W.E., and Wood W.G. Simvastatin protects neurons from cytotoxicity by up-regulating Bcl-2 mRNA and protein. J. Neurochem. 101 (2007) 77-86